# Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed

> **NCT00644735** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 750 (estimated)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT00644735
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2009-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00644735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00644735, "Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00644735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*